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Overexpression of the deubiquitylase ubiquitin-specific peptidase
22 (USP22) is a marker of aggressive cancer phenotypes like
metastasis, therapy resistance, and poor survival. Functionally,
this overexpression of USP22 actively contributes to tumorigene-
sis, as USP22 depletion blocks cancer cell cycle progression in vitro,
and inhibits tumor progression in animal models of lung, breast,
bladder, ovarian, and liver cancer, among others. Current models
suggest that USP22 mediates these biological effects via its role in
epigenetic regulation as a subunit of the Spt-Ada-Gcn5-acetyltransferase
(SAGA) transcriptional cofactor complex. Challenging the dogma,
we report here a nontranscriptional role for USP22 via a direct
effect on the core cell cycle machinery: that is, the deubiquitylation
of the G1 cyclin D1 (CCND1). Deubiquitylation by USP22 protects
CCND1 from proteasome-mediated degradation and occurs sepa-
rately from the canonical phosphorylation/ubiquitylation mechanism
previously shown to regulate CCND1 stability. We demonstrate that
control of CCND1 is a key mechanism by which USP22 mediates its
known role in cell cycle progression. Finally, USP22 and CCND1 levels
correlate in patient lung and colorectal cancer samples and our
preclinical studies indicate that targeting USP22 in combination with
CDK inhibitors may offer an approach for treating cancer patients
whose tumors exhibit elevated CCND1.
USP22 | CCND1 | cell cycle | SAGA | deubiquitylation
Ubiquitin-specific peptidase 22 (USP22) is a deubiquitylatingenzyme that functions as a subunit of the human Spt-Ada-
Gcn5-acetyltransferase (SAGA) transcriptional coactivator com-
plex (1–3). Within SAGA, USP22 catalyzes histone H2A and H2B
deubiquitylation, thereby altering chromatin structure and gene
transcription (1, 2, 4). Elevated USP22 expression is tightly cor-
related with aggressive behavior in human cancer and it was ini-
tially identified as a member of an 11-gene “death-from-cancer”
signature linked to poor prognosis (5, 6). Further investigation
found that USP22 is not only a marker of aggressive tumor phe-
notypes but also plays a causal role in driving aggressive cancer. At
the cellular level, USP22 is critical for progression through the
G1 phase of the cell cycle (7–13).
Biochemically, USP22 deubiquitylates substrates beyond nu-
cleosomal histones, including FBP1 and TRF1 (14, 15). How-
ever, there has been limited success in linking direct substrates of
USP22 to its potent biological phenotypes, including its role in
appropriate G1–S transition. To generate a comprehensive un-
derstanding of USP22 substrates and how they might contribute
to USP22 function, we conducted an unbiased proteome-wide
screen. While the screen confirmed known substrates of USP22,
including histones H2A and H2B, the sole component of the
core cell cycle machinery identified as a USP22 substrate in this
screen was the G1 phase cyclin CCND1.
Further analysis of the USP22–CCND1 relationship revealed
that USP22 directly reverses polyubiquitylation of CCND1 via a
pathway distinct from protein-destabilizing GSK3β phosphoryla-
tion and ultimately protects CCND1 from proteasome-mediated
degradation (16, 17). D-type cyclins are rate-limiting regulators of
G1–S progression in mammalian cells, primarily via their ability to
bind and activate the kinases CDK4 and CDK6 (18). Consistent
with the control of CCND1 levels by USP22, Food and Drug
Administration (FDA)-approved CDK inhibitors are epistatic
with USP22 depletion in the growth suppression of cancer cells.
Collectively, these findings define a previously unknown pathway
of CCND1 regulation and establish a mechanistic link between
USP22, CCND1, and cancer cell cycle progression that expands
potential therapeutic strategies for cancers with elevated CCND1.
Results
Loss of USP22 in Cancer Cells Results in Defective G1/S Cell Cycle
Transition. The ubiquitin hydrolase USP22 has been causally
linked to aggressive growth in human tumor cells in vitro and in
vivo (1, 8–13, 19–25). Consistent with this, depletion of USP22 in
the nonsmall-cell lung cancer line H1299 results in a marked
decrease in cell number (Fig. 1 A and B). This observation was
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consistent using USP22 shRNA vectors efficiently targeting dis-
tinct regions of the transcript (Fig. 1C). A priori, the decrease in
cell number caused by USP22 depletion might result from either
a defect in cell cycle progression or enhanced cell death. How-
ever, directly assessing cell viability and apoptosis revealed no
significant changes upon USP22 depletion (Fig. 1 D–H), sug-
gesting that the defect in cell number was unlikely due strictly to
cell death. In contrast, cell cycle analysis revealed that USP22
knockdown elicited a substantial increase in population of cells
in the G1 phase and a concomitant reduction of cells in S phase
(Fig. 1 I and J and SI Appendix, Fig. S1 F and G). G1 arrest in the
absence of increased cell death was also observed following
USP22 depletion in the human breast cancer cell line MCF7,
human prostate cancer cell line PC3, and human colon cancer
cell line HCT116 (SI Appendix, Figs. S1–S3).
Proteomic Analysis (UbiScan) Identifies CCND1 as a Candidate Substrate
of USP22. To understand the mechanistic basis of this cell cycle
phenotype, a proteome-wide screen for USP22-dependent ubiq-
uitylation was conducted. This screen analyzed the USP22-
dependent accumulation of ubiquitylated proteins in HCT116 cells,
where protein degradation was blocked by inhibition of the protea-
some. This analysis relies on affinity capture of ubiquitylated peptides
using an antibody specific for the di-glycine tag that remains linked to
ubiquitylated lysine residues following proteolysis by trypsin (26).
Enriched ubiquitylated peptides were subject to LC-MS/MS analysis
for quantitative profiling of nonredundant ubiquitylated sequences
searched against National Center for Biotechnology (NCBI) Homo
sapiens protein database. Significant hits were defined with a 2.5-fold
cut-off between compared samples, a minimum peptide intensity of
2 × 105, and a maximum percent coefficient of variation of 50%.With
the stringency parameters outlined above, 145 peptides were identi-
fied whose ubiquitylation levels increased upon USP22 depletion. In
addition, 203 peptides were identified whose ubiquitylation levels
decreased. As a ubiquitin hydrolase, USP22 depletion results in an
increase in the ubiquitylation status of its direct substrates. Con-
versely, proteins containing ubiquitylation sites that decrease upon
USP22 depletion are presumably indirect targets.
Relative to the goal of understanding the mechanism by which
USP22 impacts cell cycle regulation, proteomic analysis revealed
the D-type cyclin CCND1 as a potential USP22 substrate in this
screen. Of the 348 high-confidence proteins detected with al-
tered ubiquitylation status in the absence of USP22, CCND1 was
the only cyclin, CDK, or CDK inhibitor identified. Upon USP22
depletion, five distinct lysines within CCND1 were detected as
potential sites of elevated ubiquitylation (K33, K46, K50, K112,
and K114) with an increase relative to control ranging from 2.5-
to 3.5-fold (Fig. 2 A–C and SI Appendix, Table S1). Classifying
ubiquitylation patterns relied on the identification of single or
multiple di-glycine remnants on specific CCND1 peptides. Dual
di-glycine remnants at both K33 and K46 were observed on a
single peptide, indicating simultaneous ubiquitylation events on
the same CCND1 molecule. As K112 and K114 can reside in the
same peptide after partial cleavage by trypsin, this analysis did
not provide an unambiguous identification of which lysine is the
natural acceptor site.
Fig. 1. Loss of USP22 in cancer cells results in G1-
phase cell cycle arrest. H1299 human lung cancer
cells depleted of USP22 via infection with an shRNA-
encoding lentivirus (or a luciferase shRNA as a con-
trol). After selection, cells counted and plated at
80,000 cells/mL on day 2 postinfection. (A) Cell
number determined by direct counting of triplicate
wells in a six-well plate via hemocytometer at the
indicated time points. (B) Colony growth assessed via
fixation and methylene blue staining of foci at day
7 postinfection. (C) Efficient knockdown of USP22
confirmed by both qRT-PCR and immunoblot (IB). (D)
Cell viability quantified via flow cytometry. (E)
Quantification of three experimental replicates rep-
resenting average and SD of percent cell death,
based on permeability. (F) Apoptosis measured by
Annexin V-PE and 7AAD DNA staining, quantified by
flow cytometry. (G) Quantification of three experi-
mental replicates representing average and SD of
percent apoptosis based on population of Annexin
V-PE+ cells. NS, not significant. (H) PARP and CASPASE-3
(CAS-3) cleavage demonstrated by IB. The black
arrowhead indicates cleaved species. (I) Progression
through the cell cycle determined by EdU incorpo-
ration and PI staining followed by flow cytometry;
the percent of cells in G1 phase is represented in
blue. (J) Quantification of three experimental rep-
licates of cell cycle phase distribution. Error bars
indicate SD based on three independent experi-
ments. *P < 0.05, **P < 0.02, ***P < 0.005.


























































The functional relevance of USP22 regulated ubiquitylation
was assessed by examining steady-state CCND1 levels upon
USP22 depletion. In the colon cancer cell line HCT116 used in
the original screen and in the cancer lines H1299, MCF7, and
PC3 (Fig. 2D), USP22 depletion resulted in a decrease in
CCND1 protein levels. This effect on steady-state CCND1 was
also observed in the human dermal fibroblast cell line 2091,
linking USP22 to the regulation of CCND1 in both normal and
malignant cells (Fig. 2E). Furthermore, USP22 regulation of
CCND1 occurred independently of p53 activity (SI Appendix,
Fig. S4E). The elevated ubiquitylation and decreased steady-
state levels of CCND1 seen after USP22 depletion suggest that
deubiquitylation of CCND1 by USP22 may protect it from
proteasomal degradation.
Levels of both USP22 and CCND1 are elevated in human
cancer, raising the possibility that elevated USP22 might pro-
tect CCND1 from degradation. To assess this, a conditional
allele of USP22 was ectopically expressed. Over a 5-d course of
USP22 induction, CCND1 levels increased (Fig. 2F). Levels of
the CCND1 partners CDK4 and CDK6 were simultaneously
Fig. 2. Proteomic analysis (UbiScan) identifies CCND1 as a candidate substrate of USP22. (A) USP22-dependent regulation of CCND1 ubiquitylation status
identified by UbiScan. This unbiased proteomic analysis was performed in HCT116 cells following USP22 depletion and proteasome inhibition. Ubiquitylated
lysine residues and their reported functional roles in CCND1 are listed, along with potential links to cancer mutations. (B) Efficient knockdown of
USP22 shown by IB for samples subjected to UbiScan analysis. (C) Schematic representation of CCND1 indicating known posttranslational modifications and
ubiquitylated residues identified by UbiScan. (D) Levels of CCND1 protein following USP22 depletion determined by IB in HCT116, H1299, MCF7, and PC3 cells.
(E) CCND1 protein levels following loss of USP22 evaluated in nonmalignant, human fibroblast 2091 cells. (F) FLAG-tagged USP22 was ectopically expressed in
HCT116 cells via a stably integrated tetracycline-inducible vector. CCND1 and CDK4/6 protein levels assessed following USP22 induction for the indicated time
points. (G) Protein levels of phosphorylated pRB, RB, CCND1, CCND2, CCND3 CDK4, and CDK6 assessed by IB in H1299 cells. (H) CCND1 mRNA levels measured
by qRT-PCR following USP22 depletion in H1299, MCF7, and PC3 cells.



















































examined, with no apparent impact of USP22 induction on levels
of either kinase.
D-type cyclins are the rate-limiting partners of CDK4/6, which
together form an active kinase complex whose canonical sub-
strates include the retinoblastoma (RB) tumor suppressor pro-
tein (27, 28). Phosphorylation of RB by CCND-CDK4/6 is
essential for efficient progression through the G1 to S transition
of the cell cycle (29–31). To probe the functional consequences
of USP22-mediated regulation of CCND1 protein levels, the
phosphorylation status of RB was assessed. Depletion of USP22
from H1299 cells resulted in the expected decrease in CCND1
levels and this was accompanied by a defect in RB phosphory-
lation (Fig. 2G). Consistent with results from conditional USP22
expression, depletion of USP22 had no substantive impact on
CDK4 or CDK6 protein levels. Similarly, levels of the CCND1
family members CCND2 and CCND3 were not impacted by
USP22 depletion, suggesting separate regulatory mechanisms for
these otherwise closely related proteins (Fig. 2G and SI Appendix,
Fig. S5). USP22 is a critical component of the SAGA transcription
regulatory complex, and therefore might exert its impact on
CCND1 protein levels indirectly via changes in transcription of the
CCND1 locus. However, quantitative analysis of CCND1 tran-
script levels in cells revealed no decrease after USP22 depletion,
suggesting that USP22 affects CCND1 protein stability (Fig. 2H).
In addition to USP22, the SAGA complex contains ∼20 proteins,
including the GCN5/KAT2A acetyltransferase and ATXN7L3, a
subunit tightly bound to USP22 and critical for its catalytic activity
(32). Depletion of either of these SAGA subunits resulted in de-
creased CCND1 protein, which phenocopied the decrease in
CCND1 observed upon USP22 depletion. As with USP22, the
effects of GCN5 and ATXN7L3 on CCND1 protein could not be
explained by an effect on CCND1 mRNA (SI Appendix, Fig. S6).
USP22 Stabilizes CCND1 Protein, Protecting It from Proteasome-
Mediated Degradation. Collectively, these findings suggest a
model in which USP22 directly deubiquitylates CCND1, thereby
protecting it from polyubiquitylation and proteasome-mediated
degradation. To test this model, the ability of proteasome in-
hibition to reverse the effects of USP22 depletion on CCND1
protein levels was tested. In cells depleted of USP22, treatment
with either of two proteasome inhibitors (MG132 or epoxomicin)
largely rescued the loss of CCND1 protein (Fig. 3A). This
proteasome-dependent control of CCND1 by USP22 was con-
sistent in human cell lines from multiple lineages, using multiple
shRNAs (Fig. 3B). In comparison, treatment with a pan calpain
inhibitor (ALLN) resulted in only a modest rescue of CCND1
levels (Fig. 3A). Taken together, these data suggest that USP22
regulates CCND1 via a proteasome-dependent mechanism.
Providing further evidence that USP22 controls CCND1 levels
largely via effects on the CCND1 protein, ectopically expressed
CCND1 was sensitive to USP22 depletion to an extent similar to
endogenously expressed CCND1. Furthermore, similar to en-
dogenous CCND1, the impact of USP22 depletion on ectopic
CCND1 was largely rescued by proteasome inhibition (Fig. 3C).
Protection of CCND1 from polyubiquitylation and degrada-
tion by USP22 predicts an impact on CCND1 protein half-life.
This was assessed using cycloheximide (CHX) to block CCND1
translation and subsequently following the protein decay rate
over time. In control cells, this analysis demonstrated a rela-
tively short half-life for CCND1 (∼20 min), consistent with
previous reports (33). Depletion of USP22 resulted in an even
more rapid destruction of CCND1, yielding a half-life of ∼10 min.
This acceleration in CCND1 decay rate results from enhanced
proteasome-mediated degradation, as treatment with epox-
omicin (EPX) fully stabilized the protein (Fig. 3 D–F).
USP22 Catalyzes CCND1 Protein Polyubiquitylation Independent of
T286 Phosphorylation. An additional prediction of the model is
that USP22 depletion should result in the accumulation of high
molecular-weight species of polyubiquitylated CCND1, particu-
larly in the context of proteasome inhibition. Long exposure of a
Western blot for CCND1 from USP22-depleted cells indeed
Fig. 3. USP22 protects CCND1 protein from proteasome-mediated degradation. (A) CCND1 protein levels assessed in the presence of the proteasome in-
hibitors MG132 or EPX or the Calpain I inhibitor ALLN in H1299 cells. (B) USP22 depletion in H1299, MCF7, and PC3 cells accomplished using two distinct shRNA
constructs. CCND1 protein levels assessed in the presence or absence of the proteasome inhibitor EPX. (C) The effect of USP22 depletion on the levels of
ectopically expressed CCND1 assessed in H1299 cells. The impact of proteasome inhibition examined following MG132 treatment. (D) CCND1 protein half-life
evaluated by treatment of cells with CHX for the indicated times. (E) CCND1 protein levels quantified for three CHX time-course experiments, followed by
normalization to actin. Initial CCND1 levels set to 100%. (F) Bar graph representing the average and SD of CCND1 protein half-life for the experiments plotted
in E. Error bars indicate SD based on three independent experiments. **P < 0.02.


























































revealed high molecular-weight species of CCND1. These spe-
cies appear to represent polyubiquitylated CCND1 as protea-
some inhibition triggered their appearance, even in the absence
of USP22 depletion (Fig. 4A and SI Appendix, Fig. S7A). Tran-
sient interactions between a deubiquitylating enzyme and its
substrate are often difficult to capture, presumably due to the
rapid hydrolysis of the isopeptide bond linking ubiquitin to a
target lysine residue (34). However, ectopic expression of both
proteins followed by immunoprecipitation (IP) demonstrated an
in vivo interaction (SI Appendix, Fig. S7B). To address whether
CCND1 is a direct substrate of USP22, these proteins were sub-
jected to an in vitro ubiquitylation and successive deubiquitylation
reaction, using a strategy described previously (35). The
SCFFBXO4, CCND1/CDK4, and USP22 complexes were purified
from Sf9 cells infected with the relevant baculovirus expression
vectors. To ubiquitylate CCND1 protein, the SCFFBXO4 complex
and CCND1/CDK4 complex were combined with E1, E2 (UbcH5a),
ATP, and ubiquitin. Following ubiquitylation, samples were
incubated with or without purified USP22 complex for times in-
dicated. The addition of purified USP22 complex to the reaction
resulted in a marked decrease in polyubiquitylated CCND1 (Fig.
4B). Alternative in vitro assays performed with complexes pre-
served and isolated from mammalian cells further demonstrated
deubiquitylate of CCND1 by USP22 (SI Appendix, Fig. S7C).
To define whether the high molecular-weight species of CCND1
that appear upon USP22 depletion represent polyubiquitylated
molecules, lysates were subjected to purification using tandem
ubiquitin binding elements (TUBEs). Subjecting lysates fromUSP22-
depleted cells to this in vitro purification demonstrated that the high
molecular-weight forms of CCND1 reflected polyubiquitylated spe-
cies. Addition of a promiscuous global ubiquitin hydrolase to the
reaction collapsed the high molecular-weight species of CCND1 to
the molecular weight of unmodified CCND1, confirming their
identity as polyubiquitin-bearing molecules (Fig. 4 C and D).
Previous work suggested that mutation of all CCND1 lysines
to arginine confers protection from proteasome-dependent deg-
radation, while single mutations only offered a modest increase
in the stability of CCND1 (36). To determine whether regulation
of CCND1 by USP22 depends on the presence of lysine residues,
an HA-tagged CCND1 mutant containing arginine conversions
of all lysine residues from K33 to K123, was assessed for sensi-
tivity to USP22. Compared with HA-CCND1 WT, HA-CCND1
K33-123R partially rescued the destabilization of CCND1 observed
with loss of USP22 (Fig. 4E). Collectively, these data imply that
USP22 can directly remove polyubiquitin chains from CCND1 lysine
residues and protect it from proteasome-mediated degradation.
Previously, the ubiquitin hydrolase USP2 was reported to
deubiquitylate CCND1 (37). In H1299 cells, depletion of either
Fig. 4. USP22 directly deubiquitylates CCND1 pro-
tein independent of phosphorylation at T286. (A)
H1299 cell lysates subjected to an endogenous
CCND1 IP under nondenaturing conditions using A/G
beads. Precipitates probed for CCND1 to detect high
molecular-weight species, presumably ubiquitylated
CCND1. (B) Sf9 cells were infected with baculovirus-
expressing Flag-Fbxo4, Flag-cyclin D1, CDK4, HA-α-B-
crystallin, HA-Cul1, HA-Skp1, and HA-Rbx1. SCFFbxo4
complex and CCND1/CDK4 complex then purified
using anti-FLAG M2 and combined with E1/E2 li-
gases, ATP, and ubiquitin for 30 min at 37 °C to
ubiquitylate CCND1 protein. Postubiquitylation as-
say, the CCND1/CDK4 complex was isolated and in-
cubated with or without USP22 at 37 °C for indicated
times in deubiquitylation buffer. Protein levels de-
tected by IB; high molecular-weight CCND1 species
indicative of polyubiquitylated CCND1. (C) HCT116
cell lysates subjected to in vitro analysis of CCND1
ubiquitylation status following USP22 depletion us-
ing UbiTest, as described in the Materials and
Methods. Cells treated with MG132 before harvest
and lysates generated using buffer containing pro-
tease mixture inhibitor, pan DUB inhibitor PR619,
and the conventional chelator o-phenanthroline.
Eluates then either left undigested (lanes 1 and 2) or
subsequently digested with a global-DUB to strip
polyubiquitin (lanes 3 and 4). Protein levels were
detected by IB. The black arrowheads indicate unit
length CCND1 (nonubiquitylated) and the green ar-
rowheads indicate high molecular-weight species
presumably representing ubiquitylated CCND1. (D)
Schematic representing UbiTest experimental design
from C. (E) H1299 cells made to express HA-tagged
CCND1 WT or mutant with lysines from K33-K123.
USP22 depleted in cells with shRNA-mediated lenti-
virus and CCND1 protein levels were assessed via
anti-HA by IB. (F) HA-tagged CCND1 was expressed
in H1299 cells as either WT or with phosphorylation
site mutation T286A. Following USP22 depletion
with two distinct shRNA constructs, cells were lysed and CCND1 protein levels were assessed by IB. (G) H1299 cells expressing the WT or T286A isoforms of HA-
tagged CCND1 were subjected to USP22 depletion and subsequent analysis by IB in the presence or absence of proteasome inhibition (EPX). (H)
Phosphorylation-dependence of USP22-depletion induced CCND1 degradation was assessed by inhibition of the T286 kinase GSK3β via treatment with TSW-
119. Following depletion of USP22, CCND1 protein levels were assessed by IB. The established GSK3β pathway substrate β-catenin was included as control for
TSW119 efficacy.



















































USP2 or USP22 resulted in similar decreases in steady-state
CCND1, and effects of both deubiquitinating enzymes (DUBs)
were partially rescued by proteasome inhibition (SI Appendix,
Fig. S8A). No interdependent changes in protein levels were
detected in USP2 and USP22 upon knockdown, suggesting that
USP22 depletion does not result in decreased steady-state CCND1
via an indirect effect on USP2 levels. Moreover, loss of CCND1 upon
depletion of either USP2 or USP22 had similar functional con-
sequences and similarly increased high molecular-weight poly-
ubiquitylated CCND1 species (SI Appendix, Fig. S8 B and C).
The best-characterized pathway of CCND1 degradation relies
on its phosphorylation-dependent export from the nucleus fol-
lowed by polyubiquitylation and proteasome-mediated degrada-
tion in the cytoplasm (17, 38). To directly test the phosphorylation
dependence of the effect of USP22 on CCND1, CCND1 mutants
containing alanine conversions at either T286 or T288 were assessed
for sensitivity to USP22. For both of these phosphorylation-defective
mutants, depletion of USP22 had effects similar to its effect on
WT CCND1 (Fig. 4F and SI Appendix, Fig. S9A). Further analysis
demonstrated that inhibition of proteolysis rescued the USP22
effect on mutant T286A CCND1, as it did for WT CCND1 (Fig.
4G). Previous studies have identified GSK3β as a primary kinase
responsible for CCND1 phosphorylation at T286 (39). To confirm
that USP22 affects endogenous CCND1 stability independent of
phosphorylation at this site, USP22-depleted cells were treated
with the GSK3β inhibitor TSW-119. Consistent with the obser-
vation that USP22 depletion affects mutant T286A CCND1 sta-
bility, inhibiting phosphorylation at T286 with TSW-119 resulted
in no alteration of endogenous CCND1 protein or phosphorylated
CCND1 (Fig. 4H and SI Appendix, Fig. S9B). Because phos-
phorylation at T286 acts as a precursor to nuclear export, CCND1
levels in separate cellular fractions were assessed upon depletion
of known CCND1-dependent USP2 and USP22. CCND1 in
whole-cell lysates and in the cytoplasmic fraction were both de-
creased upon depletion of USP22 or USP2. A long exposure of the
Western blots suggests that the nuclear pool of CCND1 decreased
following USP22 depletion, while USP2 depletion had little effect (SI
Appendix, Fig. S10A). To gain a more precise understanding of the
cellular CCND1 pools that are targeted by USP22, nuclear fractions
were further subdivided into chromatin-bound and chromatin-free
protein pools (SI Appendix, Fig. S10B). These findings suggest
that USP22 and USP2 may have distinct mechanisms of action
on CCND1, with USP22 controlling a CCND1 degradation
pathway that is at least partially distinct from the canonical,
phosphorylation-dependent pathway.
Ectopic CCND1 Protein Partially Rescues the Aberrant Cell Proliferation
Phenotype Observed with USP22 Depletion. As reported here and
elsewhere, USP22 plays a significant role in cell cycle progression,
with the greatest impact on the G1 phase (Fig. 1). Because
CCND1 is among the central regulators of G1 progression in
mammalian cells, we tested the hypothesis that CCND1 deficiency
contributes to the effect of USP22 depletion on G1 progression.
Despite data shown in Fig. 3 demonstrating USP22 regulating
exogenous CCND1, a modest level of CCND1 was established by
transient expression (Fig. 5A). Ectopic expression of CCND1 in
cells depleted of USP22 caused an increase in proliferation rela-
tive to control cells (Fig. 5 B and C). Further analysis confirmed
that this rescue occurred primarily via a reduction in transit
through G1 (Fig. 5D). That the aberrant cell proliferation ob-
served with USP22 depletion can be partially rescued by ectopic
CCND1 protein suggests that stabilization of CCND1 is a key
event in the USP22-mediated regulation of the cell cycle.
USP22 Regulation of CCND1 Has Clinical Consequences as CDK4/6i
Treatment Rescues the G1 Phenotype Associated with USP22
Overexpression. Overexpression of CCND1 is a well-established
hallmark of human cancer (40, 41). Similarly, USP22 over-
expression is conserved among many aggressive forms of cancer
(5, 6, 42). To assess any potential correlation between USP22
elevation and CCND1 elevation, human tumor tissue microarrays
were quantified for levels of each protein. Among 110 colorectal
carcinoma samples and 110 lung carcinoma samples (Fig. 6 A and
B and SI Appendix, Fig. S11), a significant correlation between
CCND1 and USP22 protein levels was observed. Elevated
CCND1 activity and expression in cancer can be targeted clinically
using FDA-approved CDK inhibitors. The findings presented
here suggest that tight regulation of USP22 is essential for G1–S
transition via CCND1 regulation, raising the possibility that
USP22 might represent a therapeutic target. To assess the ther-
apeutic potential of this pathway, HCT116 cells engineered to
overexpress USP22 were treated with the CDK inhibitor PD-
0332991. As expected, induction of ectopic USP22 resulted in
an enhanced G1 exit (Fig. 6 C and D) and increased CCND1
protein levels (Fig. 6E). Strikingly, inhibiting downstream CCND1/
CDK activity with PD-0332991 in USP22-overexpressing cells was
sufficient to reverse the effect of USP22 on cell-cycle progression.
Furthermore, HCT116 cells treated with PD-0332991 demonstrated
a similar defect in G1–S transition to that of cells with reduced
USP22 expression. Concomitant depletion of USP22 and inhibition
of CDK4/6 resulted in no additive cell cycle or death response (SI
Fig. 5. Ectopic expression of CCND1 provides a
partial genetic rescue of the cell cycle phenotype
observed with USP22 depletion. H1299 cells were
transfected with a vector encoding 3XFLAG-tagged
CCND1, followed by USP22 depletion. (A) Immuno-
blot demonstrating efficient knockdown of USP22,
exogenous 3XFLAG-CCND1, and endogenous CCND1
expression. (B) Cell number was determined by
manual counting of experimental triplicates at each
of the postdepletion time points indicated. Error
bars indicate SD based on three independent ex-
periments. (C) Methylene blue-stained foci of rep-
resentative plates from B. (D) At day 7 following
USP22 depletion, cells were harvested and cell cycle
profile was determined by PI staining and flow
cytometry. G1-phase cells were gated (in blue) as
percent of the total population. **P < 0.02.


























































Appendix, Fig. S12), suggesting that USP22 and CDK4/6 may regu-
late the same pathway in an epistatic manner. Collectively, these
findings implicate the DUB USP22 as a key regulator of CCND1,
and thereby a potential complement to current therapeutic strategies
targeting CCND1/CDK4/6 in cancer. For example, the often severe
side effects experienced by patients receiving CDK4/6, might be re-
duced by use of lower doses in combination with USP22 inhibition.
Discussion
The role of USP22 in transcription is presumed to result in large
part from its ability to remove ubiquitin from nucleosomal histones
H2A and H2B (1–3). Empirical studies have demonstrated that
USP22 can deubiquitylate nonhistone substrates as well (e.g., TRF1
and FBP) (14, 15). USP22 plays a critical role in progression
through the G1–S phase transition of the cell cycle and its activity is
Fig. 6. CCND1 and USP22 protein levels correlate in patient samples from lung and colon adenocarcinoma and CDK4/6i treatment rescues the G1 phenotype
associated with USP22 overexpression. (A) Representative images of serial sections of colon adenocarcinoma or lung adenocarcinoma BioMax tissue microarrays
stained with DAPI and either USP22 or CCND1 antibodies. (B) Graphical representation of USP22(log) expression against CCND1(log) expression in each of the
120 cases with representative cases is indicated on the graph. [Pearson’s correlation coefficient (PCC) of 0.338 for colon adenocarcinoma or 0.357 for lung ad-
enocarcinoma.] (C) FLAG-tagged USP22 was ectopically expressed in HCT116 cells via a stably integrated tetracycline-inducible vector. Following USP22 induction
and treatment with selective CDK4/6 inhibitor PD-0332991 (PD), cells were harvested and cell cycle profile was determined by assessment of DNA content with PI
staining and flow cytometry. G1-phase cells were gated (in blue) as percent of the total population. (D) Quantification of cell cycle phase distribution. Error bars
indicate SD based on three independent experiments. (E) Induction of ectopic USP22 and increased CCND1 protein levels were assessed by IB. **P < 0.02, ***P <
0.005. (F) A schematic representing the proposed model of CCND1 stabilization by deubiquitylase USP22. CCND1–CDK4/6 complex advances cell cycling via
hyperphosphorylating RB, which in turn releases E2F transcription factor from an inhibitory constraint and enables the expression of genes required for G1–S
phase transition. To regulate rapid turnover, CCND1–CDK4/6 can incur phosphorylation at Thr286 by GSK3β, a precursor to nuclear export and subsequent
polyubiquitylation by distinct E3 ligases (e.g., FBX4, PARK2, SKP2, FBXW8. . .) (66–71). Polyubiquitylated CCND1–CDK4/6 is then targeted for proteasomal deg-
radation. USP22 promotes CCND1 stabilization via removing CCND1 ubiquitin within the nucleus and/or cytoplasm and blocking degradation by the proteasome.



















































both elevated and required for the aggressive growth of numerous
cancer lineages (7–13). [Somewhat paradoxically, a role for USP22
in M phase has been proposed based on evidence that CCNB1 is
deubiquitylated by USP22 (43)]. Nonetheless, no known substrate
of USP22 explains its central biological phenotype, progression
through the G1–S cell cycle transition. These studies were un-
dertaken with the expectation that elucidating the role of USP22 in
orchestrating the G1–S progression might advance our under-
standing of aggressive growth phenotypes in cancer and inform the
development of novel therapeutics.
What remains lacking is a mechanistic understanding of which
substrates of USP22 mediate these potent effects on prolifera-
tion. Here, a proteome-wide analysis in human cells identified
proteins whose ubiquitylation is regulated by USP22. This screen
identified several high-confidence hits within proteins not pre-
viously described as USP22 substrates. As reported above, the
G1 cyclin CCND1 was validated experimentally as a direct
USP22 substrate. USP22 hydrolyzes ubiquitin at a set of specific
lysine residues on CCND1 (K33, K46, 50, K112/114). Func-
tionally, K33 ubiquitylation is implicated in nuclear localization
of CCND1 (44), and K112 and K114 ubiquitylation are linked to
the interaction of CCND1 with partners, including CDK4/6 (45–
47). The ubiquitylation of CCND1 at K46 and K50 has not been
previously reported. Notably, several of these ubiquitylation sites
are mutated in cancer, with missense mutations at K46 and
K112 reported in lymphoma and breast cancer, respectively (36).
While the detection of these lysine residues indicates preferred
sites affected by USP22, ubiquitylation demonstrates notable
promiscuity at the level of individual lysine acceptor sites (48).
Previous attempts to uncover specific residues that regulate
CCND1 proteasomal degradation have demonstrated single and
double lysine residue mutations have only modest effects on
CCND1 stability (36). This capacity of USP22 to remove poly-
ubiquitin chains protects CCND1 from proteosomal degradation,
thereby doubling its half-life and significantly elevating steady-state
CCND1 protein levels. Four central observations highlight the bi-
ological relevance of CCND1 as a substrate of USP22. First, the G1-
phase cell cycle arrest observed upon depletion of USP22 from
human cells is genetically rescued by ectopic expression of CCND1.
Second, mimicking the scenario in cancer by modest overexpression
of USP22 in cells results in a concomitant increase in steady-state
CCND1 protein levels. Third, USP22 protein levels directly cor-
relate with CCND1 levels in tumor tissue samples from both colon
and lung cancer patients. Finally, experimentally elevating
USP22 levels both increases CCND1 and drives more rapid transit
through the G1 phase of the cell cycle, an effect blocked by treat-
ment with the FDA-approved CDK4/6 inhibitor PD-0332991. These
findings appear not to be linked to the known effect of USP22 on
the SIRT1/p53 pathway (49), because they were observed in both
p53-proficient and -deficient cell lines. Collectively these findings
support a model in which elevated expression of USP22 contributes
to the aggressive growth of cancer cells in part via its ability to
deubiquitylate and stabilize the rate-limiting cyclin CCND1, thereby
promoting the G1–S transition.
The identification of the USP22-CCND1 enzyme–substrate
relationship may explain the previously reported phosphorylation-
independent ubiquitylation and degradation of CCND1 (50). Our
findings demonstrate that USP22 deubiquitylates CCND1 regard-
less of phosphorylation events at T286 or T288. Genetic evidence
that USP2 and USP22 control distinct CCND1 degradation path-
ways comes from the observation that these enzymes are not re-
dundant, with depletion of either one sufficient to destabilize
CCND1. Independent of CDK interaction, CCND1 binds nuclear
receptors (ERα, THR, PPARγ, and AR) to regulate cell pro-
liferation, growth, and differentiation (51). Furthermore, CCND1
regulates transcriptional activation by binding histone acetylases,
deacetylases, and coactivators (52). Levels of CCND1 in the cyto-
plasm decreased following depletion of either USP22 or USP2;
however, both the chromatin-bound and chromatin-free pools of
CCND1 were sensitive to USP22 depletion, while USP2 depletion
had little effect on either pool. These findings suggest that USP22 and
USP2 may regulate CCND1 via distinct pathways/mechanisms.
A number of the observations reported here suggest that
USP22 may target the unbound form of CCND1 rather than the
CDK-bound form. For example, the K112 and K114 sites on
CCND1 identified as USP22 targets reside within the CDK in-
teraction domain. Furthermore, the phosphorylation-independent
nature of CCND1 targeting by USP22 may allow new therapeutic
strategies for targeting this pathway. For example, the clinical effi-
cacy of CDK4/6 inhibitors in cancer might be complemented by
combinatorial treatment with a USP22 inhibitor, thus simulta-
neously targeting both the CDK-bound and the -free forms of
CCND1. More broadly, the identification of the critical cell cycle
regulator CCND1 as a substrate of the USP22 subunit of SAGA
broadens our understanding of this complex, which has previously
been linked primarily to direct effects on transcription.
Materials and Methods
Cell Culture, Viral Infection, Transfection, and Treatment. The human cell lines
HCT116, H1299, MCF7, PC3, and 2091 were obtained from American Type
Culture Collection (ATCC). The ectopic USP22-inducible HCT116 tetracycline
hydrochloride (TET) operable cell line was generated by cloning pcDNA3.1
FLAG-USP22 into the pLenti6.3/V5/TO-DEST vector using the Virapower T-Rex
system (ThermoFisher). All cell lines were cultured in DMEM (Mediatech)
supplemented with 10% FCS (FBS; Gemini Bio-Products) at 37 °C in 5% CO2.
As indicated, cells were infected with lentiviral shRNA plasmids corre-
sponding to USP22 (XM_042698.6-914s1c1, NM_015276.1-545s21c1), USP2
(NM_004205.3-1266s1c1, NM_004205.3-1554s1c1), ATXN7L3 (NM_001098833.1-
1008s21c1), GCN5 (NM_021078.1-2484s1c1), and control luciferase shRNA
(SHC007) that were obtained from the TRC collection (Sigma-Aldrich). Cells were
selected with 8 μg/mL puromycin 24 h after infection.
Transfection was performed using Continuum reagents according to the
manufacturer’s protocol (Gemini Bio-Products). HA-CCND1 WT, HA-CCND1
K33-123R, and HA-CCND1 T286A expression plasmids were kindly provided
by E. Dmitrovsky, MD Anderson Cancer Center, Houston, TX. HA-CCND1
T288A mutant was constructed by site-directed mutagenesis using Quik-
Change (Agilent Technologies). The previously described 3XFLAG-CCND1 WT
expression plasmid was kindly provided by R. Pestell, Baruch S. Blumberg
Institute, Doylestown, PA (53).
For indicated treatments, MG132 was used at 10 μM for 6 h (SelleckChem),
EPX at 10 μM for 6 h (SelleckChem), ALLN at 100 μM for 6 h (Abcam), CHX at
10 μg/mL as indicated (Sigma-Aldrich), TET at 2.25 μM for 5 d (Sigma-
Aldrich), PR619 at 50 μM for 30 min (Life Sensors), o-phenanthroline at
5 μM for 15 min (Life Sensors), TSW-119 at 1 μM for 12 h (Santa Cruz), and
PD-0332991 (PD) at 100 nM for 3 d (Sigma-Aldrich).
Cell Proliferation, Viability, and Cell Cycle. For growth assays, cells were seeded
at equal densities and harvested at the indicated time points. Media and treat-
ments were refreshed every 72 h. Cell number was determined quantitatively
by triplicate experiments using Trypan blue exclusion and counting by hemo-
cytometer. Cell density was visualized by methylene blue staining.
Levels of necrotic cells were assessed by Muse Count and Viability Reagent
and analyzed using the Muse Cell Analyzer as described by the manufacturer
(Millipore). To quantify apoptotic cell death, cells were collected by trypsi-
nization and stained using the Annexin V PE-7AAD apoptosis detection kit
(BD Pharmingen). Fluorescence was detected by flow cytometry CytoFlex LX
Flow Cytometer (Beckman Coulter).
Cell cycle analysis was conducted using the Click-iT EdU flow cytometry cell
proliferation assay where cells were labeled with EdU for 2 h, harvested, and
stained according to the manufacterer’s instructions (Thermo Fisher). DNA con-
tent was measured using propidium iodide (PI) staining for 30 min on cells fixed
with 70% ethanol. Cell cycle analysis was processed using the CytoFlex LX.
Immunoblotting, Cellular Fractionation, Co-IP, and mRNA Analysis. Cells were
harvested and lysed in E1A whole-cell lysate buffer supplemented with
protease inhibitor mixture (Sigma-Aldrich) and PR619. Western blotting
concentration in lysates was determined using the bicinchoninic acid (BCA)
assay and analyzed by SDS/PAGE using antibodies against CCND1 (#2978; Cell
Signaling), USP22 (#ab195289; Abcam), USP2 (#8036S; Cell Signaling), CDK4
(#sc-260; Santa Cruz), CDK6 (#3136S; Cell Signaling), FLAG (#F3165; Sigma-
Aldrich), HA (#sc-805; Santa Cruz), Ubiquitin (#sc-7905; Santa Cruz), RB (#sc-


























































50; Santa Cruz), pRB (#sc-271930; Santa Cruz), ATXN7L3 (#A302-800A;
Bethyl), GCN5 (#sc-365321; Santa Cruz), CCND2 (#3741T; Cell Signaling),
CCND3 (#2936S; Cell Signaling), phospho-CCND1 (#3300T; Cell Signaling),
FBXO4 (#YZ1779; YenZym Antibodies), CUL1 (#sc-11384; Santa Cruz), SKP1
(#2156; Cell Signaling), RBX1 (#4397; Cell Signaling), ACTIN (#sc-47778; Santa
Cruz), β-CATENIN (#8480; Cell Signaling), GAPDH (#ab9485; Abcam), ORC2
(#559266; Pharmingen), and TUBULIN (#T9026; Sigma-Aldrich).
Cellular Fractionations Were Performed as Described Previously. Cellular
fractionations were performed as described previously (54). For protein–
protein interaction studies, ∼750 μg of whole-cell lysates was used for IP.
FLAG IPs were performed by incubating lysates with 20 μL Anti-FLAGM2 Affinity
Beads (Sigma-Aldrich) for 16 h at 4 °C before Western blot analysis. Endogenous
CCND1 IPs were conducted using 5 μg of CCND1 antibody (TA329665; OriGene)
for 16 h at 4 °C and precipitates captured using protein A/G beads (Santa Cruz).
Total RNA was extracted using TRIzol (Thermo Fisher) and reverse-
transcribed using the High-Capactiy cDNA Reverse Transcription Kit (Thermo
Fisher) according to the manufacturer’s instructions. Real-time PCR was per-
formed using Fast SYBR Green (Thermo Fisher), as described previously (55),
using primer sequences are listed in SI Appendix, Table S1. In all cases, mRNA
levels between samples were normalized to actin levels.
UbiScan. Samples were analyzed using the PTMScan method as previously
described (56–58). Cellular extracts were prepared in urea lysis buffer, son-
icated, centrifuged, reduced with DTT, and alkylated with iodoacetamide.
Total protein (15 mg) for each sample was digested with trypsin and purified
over C18 columns for enrichment with the Ubiquitin K-GG Remnant Motif
antibody (#5562). Enriched peptides were purified over C18 STAGE tips (59).
Replicate injections of each sample were run nonsequentially on the instrument.
Peptides were eluted using a 72-min linear gradient of acetonitrile in 0.125%
formic acid delivered at 280 nL/min. MS/MS spectra were collected in a data-
dependent manner with an Orbitrap Elite Hybrid Ion Trap-Orbitrap Mass Spec-
trometer running XCalibur 2.0.7 SP1 using a top-20 MS/MS method, a dynamic
repeat count of one, and a repeat duration of 30 s. Real-time recalibration of
mass error was performed using lock mass (60), with a singly charged poly-
siloxane ionm/z = 371.101237. MS/MS spectra were evaluated using the Sorcerer
platform (61, 62). Files were searched against the NCBI Homo sapeins FASTA
database. Amass accuracy of ±50 ppmwas used for precursor ions and 1.0 Da for
product ions. Enzyme specificity was limited to trypsin, with at least one tryptic
(K- or R-containing) terminus required per peptide and up to four miscleavages
allowed. Cysteine carboxamidomethylation was specified as a static modification;
oxidation of methionine and a di-glycine remnant on lysine residues were
allowed as variable modifications. Reverse decoy databases were included for all
searches to estimate false discovery rates, and filtered using a 5% false-discovery
rate in Sorcerer. Peptides were also manually filtered using a ±5 ppm mass error
range and the presence of at least one K-GG on each peptide. All quantitative
results were generated using Progenesis v4.1 (Waters Corporation) to extract the
integrated peak area of the corresponding peptide assignments. Accuracy of
quantitative data was ensured by manual review in Progenesis or in the ion
chromatogram files. A 2.5-fold cut-off was used to denote changes between
samples and analytical percent coefficient of variation values were calculated for
each peptide to determine reproducibility across runs.
UbiTest. HCT116 cells were harvested after 6 d of knockdown and 4 h after
proteasome inhibitionwithMG132. Cellswere lysed in radioimmunoprecipitation
buffer supplementedwith proteasemixture inhibitor, PR619, ando-phenanthroline.
Protein lysate was incubated with α-Ub TUBE1 agarose resin, eluted, and digested
with global DUB USP2 for 2 h to remove polyubiquitylation, as recommended by
themanufacturer (LifeSensors). Undigested and digested samples were analyzed by
SDS/PAGE and Western blotting.
In Vitro Ubiquitylation–Deubiquitylation Assay. Sf9 cells were infected with
baculovirus expressing FLAG-FBXO4, FLAG-CCND1, CDK4, HA-α-B-CRYSTALLIN,
HA-CUL1, HA-SKP1, and HA-RBX1. Seventy-two hours postinfection, cells were
lysed in Tween 20 buffer [50 mM Hepes (pH 8.0), 150 mM NaCl, 2.5 mM EGTA,
1 mM EDTA, and 0.1% Tween 20 with protease and phosphatase inhibitors]. To
generate the DUB module with active USP22, Sf9 cells were infected with
baculovirus expressing FLAG-USP22N, ATXN7, ATXN7L3, and HA-ENY2. Forty-
eight hours postinfection, cells were lysed in Tween 20 buffer. Cell lysates
were subjected to anti-FLAG immunoaffinity purification to isolate USP22 within
an active DUB complex. The SCFFBXO4 complex and CCND1/CDK4 complex were
purified using anti-FLAG M2 affinity gel.
Beads with SCFFBXO4 complex and CCND1/CDK4 complex were combined
with E1, E2 (UbcH5a), ATP, and ubiquitin for 30 min at 37 °C to achieve
ubiquitylated-CCND1 protein. After reaction, beads were washed with
deubiquitylation buffer [100 mM Tris (pH 8.0), 1 mM EDTA, 1 mM DTT, and
5% glycerol]. Thereafter, the beads were incubated with or without hDUB
USP22 in deubiquitylation buffer for indicated times at 37 °C, as previously
described (63). Beads were subsequently boiled in 2× loading buffer. Proteins
were resolved in 10% SDS/PAGE gel and detected by relative antibodies.
In Vitro Deubiquitylation Assay. H1299 cells were transfected with 3XFLAG-
CCND1 and HA-Ub, or separately with FLAG-USP22. Cell lysates were sub-
jected toanti-FLAG immunoaffinitypurification to isolateFLAG-USP22and3XFLAG-
CCND1with conjugatedHA-Ub. The in vitro enzymatic assaywas performed for 2 h
at 37 °C, as previously described (63), and subjected to SDS/PAGE analysis.
Tissue Microarray and Quantitative Immunofluorescence. Tissue microarrays
consisting of formalin-fixed, paraffin-embedded colon or lung cancer spec-
imens were obtained from US Biomax, Inc. The colon array (Cat# BC051110b)
consisted of 110 cases of colon adenocarcinoma and 10 normal colon cases.
The age range of patients represented on the array was 22–86 y (median
55 y). The lung array (Cat# BC041115d) consisted of 110 cases of mixed-
pathology lung cancer and 10 normal lung cases. The age range of pa-
tients represented on the array was 15–76 y (median 57 y).
CCND1 and USP22 were detected in clinical colon and lung cancer specimens
by immunofluorescence-immunohistochemistry (IF-IHC) performed on Dako
Omnis autostainer using the TSA Plus Fluorescence Kit (Perkin-Elmer), as pre-
viously described (64). Antigen retrieval was performed using citrate buffer (pH
6.1; Dako). Rabbit monoclonal CCND1 (1:400, M3635; Dako) and rabbit poly-
clonal USP22 (1:400, HPA044980; Sigma) were individually diluted 1:400 and
coincubated withmouse monoclonal antipancytokeratin (clone AE1/AE3, M3515
1:100; Dako) for 45 min. High-resolution digital images of immuno-stained slides
were captured using the Pannoramic 250 Flash scanner (3DHistech). Quantita-
tive biomarker analysis was performed as previously described (65) using Tissue
Studio image analysis software (Definiens). Briefly, user-guided machine learn-
ing was used to generate an analysis solution to specifically quantify mean
nuclear signal intensity of each biomarker within epithelial DAPI-stained cell
nuclei of each tissue core. Statistical analyses were performed in SPSS.
Statistical Analysis. Data collected from at least three independent experi-
ments are presented as mean ± SD. Statistical testing was performed using SPSS
with differences between two groups determined by a Student’s t test. Signifi-
cance is denoted in the figures as: ***P < 0.005, **P < 0.02, and *P < 0.05.
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